Roivant Sciences’ (ROIV) “Buy” Rating Reaffirmed at Truist Financial

Truist Financial restated their buy rating on shares of Roivant Sciences (NASDAQ:ROIV) in a research report sent to investors on Monday, Benzinga reports. They currently have a $23.00 price objective on the stock.

Other equities analysts have also recently issued reports about the company. TheStreet upgraded Roivant Sciences from a d rating to a c+ rating in a report on Tuesday, February 13th. Wolfe Research assumed coverage on shares of Roivant Sciences in a report on Thursday, February 15th. They issued an outperform rating and a $17.00 price target on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Roivant Sciences in a research note on Tuesday, December 12th. They issued a buy rating and a $14.00 price target for the company. HC Wainwright cut their target price on shares of Roivant Sciences from $18.00 to $17.00 and set a buy rating on the stock in a research note on Wednesday, February 14th. Finally, Bank of America increased their price objective on shares of Roivant Sciences from $11.00 to $12.00 and gave the company a neutral rating in a research report on Tuesday, January 2nd. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of Moderate Buy and a consensus target price of $16.50.

Roivant Sciences Stock Up 7.5 %

NASDAQ ROIV opened at $10.84 on Monday. The stock has a market capitalization of $8.74 billion, a PE ratio of 2.08 and a beta of 1.37. The company has a debt-to-equity ratio of 0.06, a current ratio of 27.79 and a quick ratio of 27.79. The business has a fifty day moving average price of $10.74 and a two-hundred day moving average price of $10.38. Roivant Sciences has a fifty-two week low of $6.97 and a fifty-two week high of $13.24.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Tuesday, February 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.07. The business had revenue of $37.14 million during the quarter, compared to analyst estimates of $30.72 million. Roivant Sciences had a net margin of 3,624.14% and a negative return on equity of 33.38%. Equities analysts expect that Roivant Sciences will post -1.36 earnings per share for the current fiscal year.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 96,950 shares of Roivant Sciences stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $10.92, for a total transaction of $1,058,694.00. Following the completion of the sale, the chief operating officer now owns 532,207 shares of the company’s stock, valued at approximately $5,811,700.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, COO Eric Venker sold 96,950 shares of Roivant Sciences stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $10.92, for a total value of $1,058,694.00. Following the completion of the transaction, the chief operating officer now owns 532,207 shares in the company, valued at approximately $5,811,700.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Vivek Ramaswamy sold 3,000,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $11.05, for a total transaction of $33,150,000.00. Following the completion of the transaction, the insider now directly owns 51,929,426 shares in the company, valued at $573,820,157.30. The disclosure for this sale can be found here. 4.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ROIV. Dagco Inc. acquired a new position in shares of Roivant Sciences during the 4th quarter worth about $27,000. Citigroup Inc. grew its position in Roivant Sciences by 1,803.6% during the 1st quarter. Citigroup Inc. now owns 5,749 shares of the company’s stock worth $28,000 after purchasing an additional 5,447 shares during the last quarter. Royal Bank of Canada increased its stake in Roivant Sciences by 60,550.0% in the 1st quarter. Royal Bank of Canada now owns 6,065 shares of the company’s stock valued at $30,000 after buying an additional 6,055 shares during the period. FNY Investment Advisers LLC purchased a new stake in shares of Roivant Sciences in the fourth quarter valued at approximately $33,000. Finally, Headlands Technologies LLC purchased a new stake in Roivant Sciences during the fourth quarter worth about $36,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.